Reducing the risk of heart failure in diabetes mellitus: review of new therapeutics

Simple item page
dc.contributor.authorGodbole, Shreeharshen_US
dc.contributor.authorGodbole, Shreerangen_US
dc.date.accessioned2020-04-23T08:01:42Z
dc.date.available2020-04-23T08:01:42Z
dc.date.issued2020-04
dc.description.abstractDiabetes mellitus (DM) and heart failure (HF) are closely related: patients with diabetes have an increased risk of developing HF and those with HF are at higher risk of developing diabetes. When the two diseases are considered individually, HF has a much poorer prognosis than diabetes mellitus; therefore, treatment of HF is a priority in these group of patients. There are many drugs now available to achieve glycemic control in individuals with DM. However, as we enter an era of personalization in the management of DM, the next challenge will be the identification of therapeutic strategies that will not only achieve and maintain glycemic control, but that will also reverse existing complications. Given the high prevalence of HF in DM, there is a strong imperative to advance this field, with the view of identifying robust strategies that will not only improve long-term outcomes in subjects with DM and HF but also limit the likelihood of developing HF in the first place. Newer therapies like sodium- glucose transport protein- 2 inhibitors (SGLT-2 I) and sacubitril or valsartan have shown potential benefit for reducing the risk of heart failure in diabetic population. This review will summarize the new therapeutics to reduce the risk of HF in patients with DM.en_US
dc.identifier.affiliationsDepartment of Medicine, Dr. Vasantrao Pawar Medical College, Hospital and Research Centre, Adgaon, Nashik, Maharashtra, Indiaen_US
dc.identifier.affiliationsDepartment of Endocrinology, Institute for Treatment, Research in Diabetes and Endocrinology, Pune, Maharashtra, Indiaen_US
dc.identifier.citationGodbole Shreeharsh, Godbole Shreerang. Reducing the risk of heart failure in diabetes mellitus: review of new therapeutics. International Journal of Basic & Clinical Pharmacology. 2020 Apr; 9(4): 660-665en_US
dc.identifier.issn2319-2003
dc.identifier.issn2279-0780
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/200590
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber4en_US
dc.relation.volume9en_US
dc.source.urihttps://dx.doi.org/10.18203/2319-2003.ijbcp20201094en_US
dc.subjectDiabetes mellitusen_US
dc.subjectHeart failureen_US
dc.subjectMetforminen_US
dc.subjectSGLT-2 inhibitorsen_US
dc.titleReducing the risk of heart failure in diabetes mellitus: review of new therapeuticsen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijbcp2020v9n4p660.pdf
Size:
190.08 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Basic & Clinical Pharmacology